Chengdu huasun technology group Inc. , LTD.

SZSE:000790 Stock Report

Market Cap: CN¥2.5b

Chengdu huasun technology group Past Earnings Performance

Past criteria checks 1/6

Chengdu huasun technology group's earnings have been declining at an average annual rate of -16.3%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 7.1% per year. Chengdu huasun technology group's return on equity is 2%, and it has net margins of 1.2%.

Key information

-16.3%

Earnings growth rate

-17.0%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate7.1%
Return on equity2.0%
Net Margin1.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Some Investors May Be Willing To Look Past Chengdu huasun technology group's (SZSE:000790) Soft Earnings

May 06
Some Investors May Be Willing To Look Past Chengdu huasun technology group's (SZSE:000790) Soft Earnings

Recent updates

What Chengdu huasun technology group Inc. , LTD.'s (SZSE:000790) 30% Share Price Gain Is Not Telling You

Oct 28
What Chengdu huasun technology group Inc. , LTD.'s (SZSE:000790) 30% Share Price Gain Is Not Telling You

Some Investors May Be Willing To Look Past Chengdu huasun technology group's (SZSE:000790) Soft Earnings

May 06
Some Investors May Be Willing To Look Past Chengdu huasun technology group's (SZSE:000790) Soft Earnings

Revenue & Expenses Breakdown

How Chengdu huasun technology group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:000790 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 249941239030
30 Jun 249782237234
31 Mar 249622734032
31 Dec 231,0032831632
30 Sep 239393627920
30 Jun 239493927618
31 Mar 238863626421
01 Jan 238734127025
30 Sep 221,0094727022
30 Jun 221,0245027022
31 Mar 221,0135326023
01 Jan 229555628218
30 Sep 217784228615
30 Jun 217853830322
31 Mar 217794331819
31 Dec 207593832020
30 Sep 207553931927
30 Jun 207154733518
31 Mar 207185634723
31 Dec 197456235923
30 Sep 197276836625
30 Jun 197125937235
31 Mar 196593836027
31 Dec 186333134327
30 Sep 1861624031825
30 Jun 1859417030322
31 Mar 1862217328321
31 Dec 1759117225517
30 Sep 176121025510
30 Jun 17595772320
31 Mar 17592802440
31 Dec 16575822470
30 Sep 16511412460
30 Jun 16459-252590
31 Mar 16451-362550
31 Dec 15463-372500
30 Sep 15499-92560
30 Jun 15500572070
31 Mar 15525642060
31 Dec 14528662020
30 Sep 14576431840
30 Jun 14642441900
31 Mar 14616481610
31 Dec 13658501640

Quality Earnings: 000790 has high quality earnings.

Growing Profit Margin: 000790's current net profit margins (1.2%) are lower than last year (3.9%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 000790's earnings have declined by 16.3% per year over the past 5 years.

Accelerating Growth: 000790's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 000790 had negative earnings growth (-66.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).


Return on Equity

High ROE: 000790's Return on Equity (2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 18:43
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chengdu huasun technology group Inc. , LTD. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Xiaoyu QianHuatai United Securities Co., Ltd.
Kan YeXiangcai Securities